Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Michael H. Mulroy

At a glance: Michael H. Mulroy is Director at Lineage Cell Therapeutics (LCTX). Their latest SEC Form 4, filed Nov 19, 2026, reported a purchase of $26K. On file: 1 purchase line ($26K) and 0 sale lines ($0).

Disclosed holdings: about $273K of LCTX stock: 328,555 shares reported on their latest Form 4 (filed Nov 19, 2026), valued at the Nov 19, 2026 close of $0.83. This counts only LCTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Lineage Cell Therapeutics, Inc. (LCTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys−$1K
Total bought / sold$26K / $0

Michael H. Mulroy's InsiderPrint

2 trades from SEC Form 4 filings, 2024 to 2026, drawn as one fingerprint.

InsiderPrint of Michael H. Mulroy: 2 trades, 2024 to 20262024: 1 buy, 0 sales2025: 0 buys, 0 sales2026: 1 buy, 0 sales
  • Bump outward: a purchase (2)
  • Dent inward: a sale (0)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 19SEC LCTXLineage Cell Therapeutics, Inc. Buy 30,000328,555 held (+10%) $0.87 $26K -4.5%
  • Buy

    Director Michael H. Mulroy bought $26K of LCTX at $0.87 — first open-market purchase in our records.

Follow Michael H. Mulroy

Get one email when Michael H. Mulroy files a new purchase or sale. Free.

At most one email a day about Michael H. Mulroy, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.